The renal excretion of prostaglandins and changes in plasma renin during treatment with either sulindac or naproxen in patients with rheumatoid arthritis and thiazide treated heart failure.
Ten patients with rheumatoid arthritis (RA) and concomitant heart failure were treated with either naproxen or sulindac in an open randomized study to study the drugs' effects on the urinary excretion of prostaglandins on the plasma renin level and on the renal function of the group. Both drugs were given for 14 days and caused a similar and marked decrease in renal excretion of the prostaglandins PGE2 and PGF2 alpha and in plasma renin in all patients. There was no significant effect on the diastolic blood pressure, the body weight or the 24-h creatinine clearance and the clinical effect on the joint symptoms was identical. We conclude that both sulindac and naproxen inhibit the renal prostaglandin synthesis in patients with RA.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D001581:Benzothiadiazines; D004232:Diuretics; D005260:Female; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007192:Indenes / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects*; D011453:Prostaglandins / Q000652:urine; D012083:Renin / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013467:Sulindac / Q000009:adverse effects*
D001581:Benzothiadiazines; D004232:Diuretics; D007192:Indenes; D011453:Prostaglandins; D049993:Sodium Chloride Symporter Inhibitors; D013467:Sulindac; D009288:Naproxen; D012083:Renin